Binding Site hosts a series of live CME-accredited webinars presented by experts in the field of multiple myeloma and other B-cell disorders.
CME Event: MGUS, Serum Free Light Chains, and Renal Biopsies: An Innovative Approach to Uncover Plasma Cell Dyscrasias
Join us for a Webinar on March 6, 2012 at 2:00PM–3:00PM EST
(11:00pm–12:00pm PST / 12:00pm–1:00pm CST)
Space is limited.
Reserve your Webinar seat now at: www1.gotomeeting.com/register/348234105
SPEAKER:
Guillermo A. Herrera, MD
Medical Director, Nephrocor
Bostwick Laboratories, Orlando, FL
OBJECTIVES:
Following this webinar, learners should be able to:
- Discuss the importance of renal biopsy and serum free light chain assays for the diagnosis of plasma cell dyscrasia when bone marrow findings are inconclusive or when a plasma cell dyscrasia is not clinically suspected.
- Describe the pivotal role of renal pathology for the diagnosis of plasma cell dyscrasia in patients with MGUS, especially in early cases and in those with unusual clinical manifestations.
- Delineate the findings in a renal biopsy that are diagnostic of plasma cell dyscrasia when clinical suspicion is based only on identification of altered serum free light chain kappa to lambda ratios used as screening tests in patients with renal dysfunction.
If you would like to receive an invitation to our future live webinars, email us at webinars@thebindingsite.com with the subject line: WEBINARS
If you've missed any of our live webinars, you may view the recorded sessions below:
- Log in or Create an Account
- Click View this Webinar to launch
Role of the Immunoglobulin Free Light Chain Nephelometric Assay in the Management of Plasma Cell Dyscrasias
This webinar describes the role of the serum free light chain assay in the prediction of early progression of plasma cell dyscrasias and in the diagnosis of patients with primary systemic amyloidosis, and discusses the clinical utility of the newly introduced Heavy/Light Chain measurement.
Dr. Morie Gertz
MD, MACP
Roland Seidler Jr Profession & Chair Department of Medicine
Mayo Distinguished Clinician
Mayo Clinic
Rochester, MN
Practical Utilization of the Serum Free Light Chain Assay: A Front Line Perspective
This webinar illustrates the practical clinical utility of serum free light chain assays via several clinical cases. Unique attributes of the free light chain assays are discussed. The role of serum free light chains is explained in the context of newly diagnosed patients with monoclonal gammopathy (MG), management of patients undergoing therapy for MG, and management of patients with recurrent MG disorders.
Dr. Jeffrey Matous
MD
Colorado Blood Cancer Institute
Denver, CO
Paradigms in Monitoring of the Plasma Cell Tumors
In this webinar the rationale for monitoring myeloma and related diseases is discussed and the prognostic implications of measuring the serum light chains in myeloma and related diseases is explained.
Dr. Rafael Fonseca
MD, Getz Family Professor of Cancer
Deputy Director, Mayo Clinic Cancer Center
Associate Director, Center for Individualized Medicine
Mayo Clinic, Scottsdale, Arizona
Use of Free Light Chain Assays in the Management of Myeloma Kidney
This webinar discusses the role of serum free light chains (FLC) assays in the screening of patients with acute kidney injury (AKI), the importance of achieving an early reduction in serum FLC concentrations in patients with myeloma kidney, the role of new chemotherapy agents in the management of patients with myeloma kidney, and the supportive strategies for the removal of free light chains in patients with myeloma kidney.
Dr. Colin Hutchison
MD, Nephrologist, Renal Institute of Birmingham, University of Birmingham and University Hospital Birmingham, Birmingham, UK
Serum Free Light Chain Assay for Evaluation of Monoclonal Gammopathies: When, Where, and How
This webinar discusses the basis of the serum free light chain test, the available data on the utility of free light chain testing in the screening and diagnosis of monoclonal gammopathies, prognostication of monoclonal gammopathies, and assessing disease response.
Dr. Sagar Lonial
MD, Associate Professor, Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, GA
New Insights into the Application of the Free Light Chain Assay in Multiple Myeloma
This webinar provides general overview of the diagnostic value of serum free light chains assays, the importance of free light chain assays for prognosis, and their role in monitoring myeloma.
Dr. Frits van Rhee
MD, PhD, MRCP (UK), FRCPath
Director of Stem Cell Transplantation, St. Francis Hospital, Greenville, SC
Professor of Medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
The Evolving Spectrum of Kidney Pathologies Associated with Underlying Plasma Cell Dyscrasia and the Role of Serum-Free Light Chain Assays in Clinical Management
The evolving spectrum of kidney pathologies associated with plasma cell dyscrasias is discussed and the critical role of serum free light chain assays in the management of patients with low tumor burden and light chain kidney pathology is illustrated as a case-based study.
Dr. Maria Picken
MD, PhD, Professor of Pathology and Internal Medicine, Loyola University, Chicago, IL
President of Renal Pathology Society
Serum Free Light Chains in the Diagnosis and Management of Patients with Plasma Cell Dyscrasias: A Case-Based Review
The utility of serum free light chain assays in the screening, diagnosis and monitoring of patients with plasma cell dyscrasias is demonstrated through three illustrative case studies.
Dr. Don Benson Jr.
MD, PhD, Assistant Professor of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center
Evolving Strategies for the Diagnosis and Management of Monoclonal Gammopathies
Dr. Howard Robin and Dr. Parameswaran Hari discuss new strategies for screening and diagnosis of monoclonal plasma cell gammopathies. Several case studies are presented to demonstrate the clinical utility of serum free light chain assays in the management of monoclonal gammopathies and their effectiveness for screening, diagnosis and monitoring of relapse and response to therapy of patients with plasma cell disorders.
Dr. Howard Robin
Pathologist
Medical Director of Continuing Education, Sharp Healthcare
Dr. Parameswaran Hari
Associate Professor of Medicine
Director, Adult Blood and Marrow Transplant Program, Division of Neoplastic Diseases and Related Disorders
Associate Scientific Director, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin
Summary of the International Myeloma Working Group Guidelines On the Use of Serum Free Light Chain Analysis
In this 5 minute video podcast, Dr. Judith Finlay, Technical Director for The Binding Site Inc., gives a brief overview of the IMWG Guidelines on the use of serum free light chain analysis in multiple myeloma and related disorders.
Dr. Judith Finlay
Technical Director, The Binding Site Inc.
Assessing Response in Multiple Myeloma
Dr. Sagar Lonial discusses the new guidelines from the IMWG for diagnostic workup of Multiple Myeloma.
Dr. Sagar Lonial
Associate Professor, Winship Cancer Institute
Use of Free Light Chain Analysis in the Diagnosis, Prognosis and Therapy of Multiple Myeloma: The Pathologist's Point of View
Dr. Amitabha Mazumder discusses the use of free light chain analysis in the diagnosis, prognosis, and therapy of multiple myeloma focusing on the Pathologist's and Clinical Chemist's point of view. He also discusses the International Myeloma Working Group guidelines for serum free light chain analysis.
Dr. Amitabha Mazumder
Professor of Medicine and Attending Physician (Medical Oncology) in the Multiple Myeloma/Bone Marrow Transplant (BMT) Program, St. Vincent's
Amyloidosis: The Secrets Behind These Elusive Diseases
Dr. Belinda Ng gives a perspective on the latest clinical information on Amyloidosis. Dr. Ng is the first physician formally trained in Amyloidosis and is a cardiologist trained at Northwestern Memorial Hospital in Chicago, IL. She has performed significant clinical research on amyloidosis at Boston University Medical Center and has seen hundreds of amyloid patients during her career.
Dr. Belinda Ng
Physician
Serum Free Light Chain Estimation in Plasma Cell Disorders: What Have We Learned?
Dr. Shaji Kumar gives a perspective on the latest clinical information on the use of serum free light chain estimation in plasma cell disorders.
Dr. Shaji Kumar
Associate Professor of Medicine at the Mayo Clinic College of Medicine and the Mayo Medical School in the Division of Hematology in Rochester
Strategies for Optimizing Outcomes in Myeloma and Other Monoclonal Gammopathies
Dr. Maurizio Zangari gives a clinical perspective on the use and value of the serum free light chain assay.
Dr. Maurizio Zangari
Professor of Hematology and Oncology and the Director of Experimental Therapeutics at the University Of Utah School Of Medicine
A Clinical Perspective of Serum Free Light Chain Analysis
Dr. Donna E. Reece gives a clinical perspective of serum free light chain analysis.
Dr. Donna E. Reece
Princess Margaret Hospital, Toronto, ON Canada
Diagnosis and Management of Multiple Myeloma and Other Monoclonal Gammopathies
Dr. Robert A. Vescio gives a clinical perspective on diagnostic tests and therapeutic advances for multiple myeloma, monoclonal gammopathy of unknown significance (MGUS) and amyloidosis.
Dr. Robert A. Vescio
Director, Multiple Myeloma and Bone Metastases Program, Comprehensive Cancer Center, Cedars-Sinai Medical Center Los Angeles, CA
Serum Free Light Chain Assays: Value in the Diagnosis of Paraproteinemic Renal Disease
Dr. Karen van Hoeven discusses the appropriate use of blood tests for free kappa and free lambda light chains (Freelite®) and how they are interpreted. These assays were integrated into the 2006 diagnostic algorithm for multiple myeloma by the International Myeloma Working Group. Their application for the diagnosis of paraproteinemic renal disease is discussed in depth in this webinar, as it was at the NKF 2007 workshop.
Dr. Karen van Hoeven
Medical Director, The Binding Site Inc.
